Publications by authors named "Floor M Garritsen"
Article Synopsis
- The study examines patient-centred dosing of dupilumab for atopic dermatitis (AD), focusing on its effectiveness and cost savings in daily practice.
- A total of 595 adult patients were assessed, with 401 managing to successfully taper their dupilumab treatment after controlling their eczema symptoms for over a year.
- Successful tapering was achieved in 83.3% of cases, suggesting that reducing medication frequency is both effective for patient health and economically beneficial, with estimated savings of nearly €4 million.
Article Synopsis
- Clinical trials indicate that baricitinib is an effective oral treatment for moderate-to-severe atopic dermatitis, though there's limited data from everyday clinical use.
- A multicenter study assessed the treatment's effectiveness and safety over 16 weeks in 51 adults, using various outcome measurements at multiple check-ins.
- Despite some positive outcomes, a significant number of patients (43.2%) stopped treatment due to ineffectiveness or side effects, highlighting the variability in effectiveness and safety in this patient group.
Introduction: For many years, oral immunosuppressive drugs such as cyclosporine A, azathioprine, mycophenolic acid, and methotrexate were the only treatment options, in addition to topical treatment, in patients with severe atopic dermatitis (AD). Dupilumab, a monoclonal antibody targeting the IL-4 receptor alpha, is the first antibody-based treatment commercially available for the treatment of AD. In the near future, more antibody-based treatments and small molecules will become available in the treatment of severe AD.
View Article and Find Full Text PDFAtopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases. The prevalence of AD is increasing and is currently estimated at 10-20% in adults worldwide. In the majority of patients, AD can be adequately controlled with topical treatment or ultraviolet light therapy, but there is a high unmet need for effective and safe therapeutics in patients with more severe or difficult to treat AD.
View Article and Find Full Text PDFIntroduction: Oral immunosuppressive drugs are commonly used in the treatment of atopic dermatitis (AD). In patients with autoimmune- and rheumatic diseases, these drugs have been associated with lymphopenia. Lymphopenia is related to an increased risk of opportunistic infections.
View Article and Find Full Text PDFThere is uncertainty about the risk of developing non-melanoma skin cancer (NMSC), including basal cell carcinoma and squamous cell carcinoma (SCC), in patients with atopic dermatitis (AD) treated with oral immunosuppressive drugs. A total of 557 patients with AD treated with these drugs in the University Medical Center Utrecht and Groningen, the Netherlands, were analysed. NMSC after oral immunosuppressive treatment was reported in 18 patients (3.
View Article and Find Full Text PDF